Zealand Pharma A/S logo

ZEAL - Zealand Pharma A/S Share Price

DKK204.4 2.4  1.2%

Last Trade - 3:05pm

Mid Cap
Market Cap £1.02bn
Enterprise Value £889.7m
Revenue £41.2m
Position in Universe 320th / 1830
Unlock ZEAL Revenue
Relative Strength (%)
1m +2.09%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
187.7 230.9 136.3 38.0 41.3 353.3 697.9 1,159 +13.5%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ZealandPharma A/S revenues increased from DKR41.3M to DKR353.3M.Net loss increased 48% to DKR846.7M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects Labor & Related Expenses in SG increase from DKR0Kto DKR130.6M (expense), Other Administrative Expensesincrease from DKR25M to DKR105.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZEAL Revenue Unlock ZEAL Revenue

Net Income

ZEAL Net Income Unlock ZEAL Revenue

Normalised EPS

ZEAL Normalised EPS Unlock ZEAL Revenue

PE Ratio Range

ZEAL PE Ratio Range Unlock ZEAL Revenue

Dividend Yield Range

ZEAL Dividend Yield Range Unlock ZEAL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZEAL EPS Forecasts Unlock ZEAL Revenue
Profile Summary

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 1, 1997
Public Since November 1, 2010
No. of Shareholders: 17,677
No. of Employees: 329
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 43,363,969
Free Float (0.0%)
Eligible for
ZEAL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZEAL
Upcoming Events for ZEAL
Frequently Asked Questions for Zealand Pharma A/S
What is the Zealand Pharma A/S share price?

As of 3:05pm, shares in Zealand Pharma A/S are trading at DKK204.4, giving the company a market capitalisation of £1.02bn. This share price information is delayed by 15 minutes.

How has the Zealand Pharma A/S share price performed this year?

Shares in Zealand Pharma A/S are currently trading at DKK204.4 and the price has moved by -7.59% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zealand Pharma A/S price has moved by -28.1% over the past year.

What are the analyst and broker recommendations for Zealand Pharma A/S?

Of the analysts with advisory recommendations for Zealand Pharma A/S, there are there are currently 2 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zealand Pharma A/S is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Zealand Pharma A/S next release its financial results?

Zealand Pharma A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Zealand Pharma A/S dividend yield?

Zealand Pharma A/S does not currently pay a dividend.

Does Zealand Pharma A/S pay a dividend?

Zealand Pharma A/S does not currently pay a dividend.

When does Zealand Pharma A/S next pay dividends?

Zealand Pharma A/S does not currently pay a dividend.

How do I buy Zealand Pharma A/S shares?

To buy shares in Zealand Pharma A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zealand Pharma A/S?

Shares in Zealand Pharma A/S are currently trading at DKK204.4, giving the company a market capitalisation of £1.02bn.

Where are Zealand Pharma A/S shares listed? Where are Zealand Pharma A/S shares listed?

Here are the trading details for Zealand Pharma A/S:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: ZEAL
What kind of share is Zealand Pharma A/S?

Based on an overall assessment of its quality, value and momentum, Zealand Pharma A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zealand Pharma A/S share price forecast 2021?

Shares in Zealand Pharma A/S are currently priced at DKK204.4. At that level they are trading at 27.29% discount to the analyst consensus target price of 0.00.

Analysts covering Zealand Pharma A/S currently have a consensus Earnings Per Share (EPS) forecast of -36.548 for the next financial year.

How can I tell whether the Zealand Pharma A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zealand Pharma A/S. Over the past six months, the relative strength of its shares against the market has been -35.79%. At the current price of DKK204.4, shares in Zealand Pharma A/S are trading at -9.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zealand Pharma A/S PE Ratio?

We were not able to find PE ratio data for Zealand Pharma A/S.

Who are the key directors of Zealand Pharma A/S?

Zealand Pharma A/S's management team is headed by:

Alain Munoz - DRC
Jens Stenvang - DRC
Adam Steensberg - EVP
Alf Nicklasson - CHM
Ivan Moeller - SVP
Kirsten Drejer - VCH
Marino Garcia - SVP
Emmanuel Dulac - PRE
Matthew Dallas - CFO
Frank Sanders - SVP
Frederik Beck - DRC
Gertrud Rasmussen - DRC
Iben Gjelstrup - DRC
Who are the major shareholders of Zealand Pharma A/S?

Here are the top five shareholders of Zealand Pharma A/S based on the size of their shareholding:

Van Herk Investments Investment Advisor
Percentage owned: 15.4% (6.69m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 4.36% (1.89m shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 4.06% (1.76m shares)
Credit Suisse (Lux) Digital Health Equity Fund Mutual Fund
Percentage owned: 4.03% (1.75m shares)
Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 3.92% (1.70m shares)
Similar to ZEAL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.